Levodopa (L-DOPA)-induced dyskinesias (LIDs) represent the major side effect in Parkinson's disease (PD) therapy. Leucine-rich repeat kinase 2 (LRRK2) mutations account for up to 13 % of familial cases of PD. LRRK2 N-terminal domain encompasses several serine residues that undergo phosphorylation influencing LRRK2 function. This work aims at investigating whether LRRK2 phosphorylation/function may be involved in the molecular pathways downstream D1 dopamine receptor leading to LIDs. Here we show that LRRK2 phosphorylation level at serine 935 correlates with LIDs induction and that inhibition of LRRK2 induces a significant increase in the dyskinetic score in L-DOPA treated parkinsonian animals. Our findings support a close link between LRKK2 functional state and L-DOPA-induced abnormal motor behaviour and highlight that LRRK2 phosphorylation level may be implicated in LIDs, calling for novel therapeutic strategies.

LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias / J. Stanic, M. Mellone, M.D. Cirnaru, M. Perez-Carrion, E. Zianni, M.M.G. Di Luca, F. Gardoni, G. Piccoli. - In: MOLECULAR BRAIN. - ISSN 1756-6606. - 9:1(2016 May 11).

LRRK2 phosphorylation level correlates with abnormal motor behaviour in an experimental model of levodopa-induced dyskinesias

J. Stanic
Primo
;
M. Mellone
Secondo
;
E. Zianni;M.M.G. Di Luca;F. Gardoni
;
2016

Abstract

Levodopa (L-DOPA)-induced dyskinesias (LIDs) represent the major side effect in Parkinson's disease (PD) therapy. Leucine-rich repeat kinase 2 (LRRK2) mutations account for up to 13 % of familial cases of PD. LRRK2 N-terminal domain encompasses several serine residues that undergo phosphorylation influencing LRRK2 function. This work aims at investigating whether LRRK2 phosphorylation/function may be involved in the molecular pathways downstream D1 dopamine receptor leading to LIDs. Here we show that LRRK2 phosphorylation level at serine 935 correlates with LIDs induction and that inhibition of LRRK2 induces a significant increase in the dyskinetic score in L-DOPA treated parkinsonian animals. Our findings support a close link between LRKK2 functional state and L-DOPA-induced abnormal motor behaviour and highlight that LRRK2 phosphorylation level may be implicated in LIDs, calling for novel therapeutic strategies.
6-OHDA; L-DOPA; L-DOPA-induced dyskinesias; LRRK2; Parkinson's disease; phosphorylation; rat; cellular and molecular neuroscience; molecular biology
Settore BIO/14 - Farmacologia
   Cell-type and sununit specific alterations of NMDA receptors in striatum at early stages of Parkinson's disease: from molecular pathogenesis to identification of new pharmacological targets
   FONDAZIONE CARIPLO
   2014-0660

   Discinesia indotta dalla L-DOPA nella malattia di Parkinson: nuovi meccanismi e targets molecolari.
   MINISTERO DELL'ISTRUZIONE E DEL MERITO
   2010AHHP5H_002
11-mag-2016
Article (author)
File in questo prodotto:
File Dimensione Formato  
13041_2016_Article_234.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.25 MB
Formato Adobe PDF
1.25 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/432305
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
social impact